NCT07352969

A Dose Finding Study of IBI3016 in Mild to Moderate Hypertensive Patients

A Randomized, Double-blind, Placebo-controlled, Multicenter, 24 Months Treatment Duration, Dose Finding Study, to Evaluate Efficacy, Safety and Pharmacodynamics of IBI3016 in Mild to Moderate Hypertensive Patients

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 352 (estimated)
• Sponsor: Innovent Biologics (Suzhou) Co. Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of IBI3016 or placebo, given subcutaneously, every 3 or 6 months, at different dose levels in patients with mild to moderate hypertension

Detailed description

Phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and pharmacodynamics of IBI3016 in patients with mild to moderate hypertension. Multiple doses of IBI3016 will be tested against placebo, administered as subcutaneous injection.

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	IBI3016	Solution of Injection
OTHER	Placebo	0.9% sodium chloride saline solution

Timeline

• Start date: 2026-02-06
• Primary completion: 2029-03-27
• Completion: 2029-03-27
• First posted: 2026-01-20
• Last updated: 2026-01-20

Locations

1 site across 1 country: China